Navigation Links
Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of the molecular pathways researchers expected would be involved.

Prof Mario Campone, Principal Investigator at Institut Cancerologie de l'Ouest in Nantes, France, presented the findings at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

"As more targeted cancer drugs are developed, the challenge is to identify which patients will benefit from individual agents," Prof Campone said. "One of the objectives of this study was to determine molecular biomarkers that predict whether a patient's cancer is sensitive to the combination of everolimus and trastuzumab compared to trastuzumab alone."

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Many patients who initially respond to trastuzumab develop resistance.

In preclinical studies, everolimus, an oral inhibitor of an important molecule called mammalian target of rapamycin (mTOR), has demonstrated an ability to reverse trastuzumab resistance. However, the mechanisms of action involved in the reversion of trastuzumab resistance are not completely understood.

"Resistance to trastuzumab may result from several molecular alterations occurring at different levels of the downstream effectors in the PI3K/AKT pathway, all of them resulting in maintenance of signal transduction," Prof Campone explains. "Therefore, using everolimus to inhibit mTOR, a major downs
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study reveals magnitude of variation in gene expression measurements within breast cancers
2. Study opens new prospects for developing new targeted therapies for breast cancer
3. Breast cancer heterogeneity no barrier to predictive testing, study shows
4. BUSM study shows positive impact of mind-body course on well-being of medical students
5. Study finds possible alternative to bariatric weight loss surgery
6. Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning
7. Study examines effects of genetic variants for infants with neonatal abstinence syndrome
8. University of Houston engineering professor awarded grant to study melanoma treatment
9. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
10. BUSM study reveals novel mechanism by which UVA contributes to photoaging of skin
11. Study led by NUS scientists reveals escalating cost of forest conservation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 Industry analyst ... a new report titled "Markets for Self-Healing Materials: ... inorganic capsule and vascular systems, biomaterials, relevant shape ... to around $2.7 billion by 2020. ... extensive coverage of smart materials. Other recent n-tech reports ...
(Date:5/27/2015)... , May 27, 2015   Codonics ... safety systems and image documentation solutions and ... comprehensive, technologically-advanced automation solutions, is pleased to ... The Codonics® Safe Label System® (SLS), an ... conjunction with the Omnicell Anesthesia Workstation, helps ...
(Date:5/26/2015)... May 26, 2015 Research ... addition of the "Saudi Arabia Biometric Systems ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric ... is projected to grow at over 22% ... is attributed to the surging demand for better ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2
... are a leading cause of mortality and adult disability. ... are especially deadly, and there are no effective treatments ... blood glucose levels) are associated with increases in bleeding ... But Joslin Diabetes Center researchers now have identified one ...
... COLUMBIA, Mo. In an article in the Nov. 23 ... Academy of Science , researchers with Dow AgroSciences and the ... transformed into corn and soybeans, provide robust resistance to the ... soybean growers a solution to the growing problem of herbicide-resistant ...
... CORVALLIS, Ore. Research is trying to determine whether ... approaches, but a new study suggests those efforts could ... assess the nutrient status of elderly people at risk ... on self-reported dietary surveys, asks people to remember what ...
Cached Biology News:Culprit found for increased stroke injury with diabetes 22 bacterial enzymes confer resistanceto common herbicide, say MU researchers 2Study of nutrition, Alzheimer's links hampered by research approach 2
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/26qndf/nanobiotechnology ... PharmaBiotech,s new report "Nanobiotechnology Applications, Markets ... An increasing use of nanobiotechnology by ... Nanotechnology will be applied at all stages ... optimal delivery to diagnostic applications in clinical ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) has announced the addition ... Testing services - Global Forecast to 2020" report ... market is estimated to be worth around $2.5 billion ... during the forecast period of 2014 to 2020 ... protein consumption, increasing adoption of advanced genetic technologies for ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has ... "Cell Therapy - Technologies, Markets and Companies" ... describes and evaluates cell therapy technologies and methods, ... role in the practice of medicine. Hematopoietic stem ... marrow transplants. Role of cells in drug discovery ...
(Date:5/28/2015)... , May 27, 2015 Research and ... Jain PharmaBiotech,s new report "Neuroprotection - Drugs, ... This report describes the role of neuroprotection ... of the nervous system as well as in ... of the underlying mechanisms of damage to neural ...
Breaking Biology Technology:Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3
... Transgenomic, Inc. (OTC Bulletin Board: ... a novel sequencing technology, which the company has termed ... limit of detection of standard Sanger Sequencing, enriches for ... and can be run on standard Sanger Sequencing equipment. ...
... March 29, 2011 Tibotec Pharmaceuticals announced today that ... investigational hepatitis C protease inhibitor, have been accepted for ... Association for the Study of the Liver (EASL) in ... The four abstracts for TMC435 support Tibotec,s ...
... Reportlinker.com announces that a new market ... Biosimilars Approval Pathways in ... Approval of Biosimilar mABs May Face Tough ... Biosimilars Approval Pathways in ...
Cached Biology Technology:Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1% 2Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1% 3Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1% 4Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL 2Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL 3Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 2Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 3Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 4Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 5Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 6Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 7Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 8Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 9Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 10Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 11Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 12Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 13
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
...
...
BD BioCoat Osteologic Coverslips that have been sterilized by ETO gas. Coating : Osteologic&trade ,Thickness : 0.16 mm ,Diameter : 12.7 mm ,Gridded : No ...
Biology Products: